

Join us for a Grassroots Reception at Nexus 2021

Please join us for a reception at Nexus 2021 from 7-8pm MT on Tuesday, Oct. 19, where AMCP members can connect with each other and AMCP Policy & Government Relations staff about promoting managed care pharmacy through grassroots advocacy. Attendees can expect refreshments and a chance to win fun prizes. We hope to see you there!

[Register](#) for Nexus 2021.



Now approved



Kerendia[®]
(finerenone) tablets
10 mg • 20 mg

Learn more about KERENDIA >

© 2021 Bayer. All rights reserved. BAYER, the Bayer Cross, and KERENDIA are registered trademarks of Bayer. PP-FINE-US-0601-1 07/21

Eye On Washington

Expanding Access to COVID-19 Therapeutics – HHS PREP Act Declaration: Ninth Amendment

On Sept. 9, the HHS released the Ninth Amendment to Declaration Under the PREP Act for Medical Countermeasures Against COVID-19, extending the declared public health emergency. This order provides liability immunity to and expands the scope of authority for licensed pharmacists to order and administer select COVID-19 therapeutics authorized by the FDA and for pharmacy technicians and pharmacy interns to administer COVID-19 therapeutics. The announcement was part of the Biden administration's comprehensive [national action plan](#) to combat the pandemic.

Read the [fact sheet](#).

HHS Comprehensive Plan for Addressing High Drug Prices

On Sept. 9, HHS released its Comprehensive Plan for Addressing High Drug Prices in response to President Biden's July 2021 [executive order](#) on promoting competition. The plan identified three guiding principles for drug pricing reform: make drug prices more affordable and equitable, promote competition throughout the prescription drug industry, and foster scientific innovation. The plan outlines the Biden administration's legislative agenda and proposes federal regulatory actions, including, legislation authorizing CMS to negotiate prescription drug prices in Medicare Parts B and D, legislation to speed the entry of biosimilar and

Advocacy Tip

Stay up-to-date: Read AMCP's [Letters, Statements and Analysis](#) on all legislation and regulation impacting managed care pharmacy.

generic drugs, and using CMMI to test models using value-based payments in Medicare Part B.

Read [HHS's plan](#).

AMCP Virtual Legislative Days 2021

Thirty AMCP members met with lawmakers in targeted congressional offices on AMCP's key issues to explain the value of managed care pharmacy in the broader health care system. Our member advocates expressed support for the NOVEL Act, the 21st Century Cures 2.0 Act, and the permanent implementation of the provisions allowing pharmacists to administer COVID-19 tests, vaccines, and covered therapeutics.

ICYMI: Respond to AMCP Policy Action Items Survey


AMCP's Policy & Government Relations team is seeking member feedback on the importance of various state and federal policies impacting managed care pharmacy. Given the nature of the legislative and regulatory processes, which typically extend beyond a single calendar year, this survey will be conducted on an as-needed basis going forward. Please respond to the survey by Friday, Oct. 15.

[Take the survey](#).

AMCP Urges Congress to Implement Continuous Eligibility for Children in Medicaid and CHIP

On Sept. 14, AMCP joined a Medicaid stakeholder letter urging Congress to include language that requires 12-month continuous eligibility for children on Medicaid and the Children's Health Insurance Program (CHIP) in the reconciliation bill. The letter expressed concern that eligibility churn — the cycle of enrollment and disenrollment caused by administrative burdens or temporary income fluctuations — worsen health outcomes and raise the average monthly cost of Medicaid as well as the administrative costs for states, providers and health plans.

[Read the letter](#).



Now approved



Learn more
about KERENDIA >

© 2021 Bayer. All rights reserved.
BAYER, the Bayer Cross, and
KERENDIA are registered trademarks
of Bayer. PP-FINE-US-0599-1 07/21